Welcome to BioSeeker Group!

Triple Analysis: Apoptosis, Cancer Vaccines and Peptides

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3637
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Apoptosis, Cancer Vaccines and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Cancer Vaccines and Peptides.

    To find out more about Triple Analysis: Apoptosis, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
Abbott
AC Immune
Acceleron Pharma
Access
Adaptimmune
Advanced Life Sciences
Advaxis
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisoma
Anza Therapeutics
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Ardana
Argos Therapeutics
Arno Therapeutics
ArQule
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioNTech
BioSante
Biostar
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celldex Therapeutics
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Chroma Therapeutics
Cleveland BioLabs
Clinuvel
CombinatoRx
Compugen
Coronado Biosciences
Cosmo Pharmaceuticals
CreaGene
Critical Outcome Technologies
CSL
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Dendreon
DeveloGen
Digna Biotech
Dongkook Pharm
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
Exelixis
Formula Pharmaceuticals
Galena Biopharma
Generex
GenOdyssee Pharmaceuticals
GENova Biotherapeutics
Genovax
Genta
Genticel
Gerolymatos
Geron
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
GP Pharm
GPC Biotech
Gradalis
Green Cross
Gryphon Therapeutics
Harbor BioSciences
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
Immunotope
Immunovaccine
ImmuPharma
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Keryx Biopharmaceuticals
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lipotek
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Nidus Laboratories
NIH
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novelix
Novogen
NPS Pharmaceuticals
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaForm
PharmaGap
PharmaMar
Pharmexa
Pharminox
Pierre Fabre
Progenics Pharmaceuticals
ProMetic Life Sciences
Protagonist
Protherics
Q Chip
QLT
Radient Pharmaceuticals
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regulon
responsif
Rigel
Rosetta Genomics
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
Shionogi
Shire
Sigma-Tau
Soligenix
Spectrum Pharmaceuticals
SRI International
SuperGen
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Tactic Pharma
Takeda
TapImmune
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Transgene
UMN Pharma
Unigene
United Biomedical
Vaccinex
ValiRx
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VBL Therapeutics
Vectura
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
Viragen
Viralytics
Virionics
ViroMed
ViroTarg
VM Discovery
Xigen
Zelos Therapeutics
Zensun
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
abarelix
ABT-510
ADXS11-001
AE-37
AEG-35156
AEZS-108
afamelanotide
AGS-003
alvocidib
AME-133
angiopep+paclitaxel
ANZ-207
APG-101
ARQ-197
AS-101
AS-1411
astuprotimut-r
Auto TAG vaccine
AVX-701
bardoxolone methyl
belagenpumatucel-L
belinostat
bortezomib
bosutinib
BP-GMAX-CD1
BV-NSCLC-001
BZL-101
canfosfamide hydrochloride
CB-10-01
CBP-501
CDX-1307
cenersen
CG-201
cintredekin besudotox
conatumumab
corticorelin acetate
CreaVax-PC
crolibulin
CV-9103
CV-9201
CVac
DCVax-prostate
deslorelin
dinaciclib
dulanermin
E-75
emepepimut-S
enzastaurin hydrochloride
EP-100
fosbretabulin tromethamine
FPI-01
gataparsen
GI-4000
goserelin
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
Her-2/Neu peptides
Hi-8 MEL
histrelin
HS-110
ibritumomab tiuxetan
ICT-107
idronoxil
imatinib mesilate
imetelstat
imMucin
IMO-2055
interleukin-12
IPP-204106
ISA-P53-01
JX-594
kahalalide F
lanreotide
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
litronesib
lonaprisan
lumiliximab
mapatumumab
MDX-1379
MGN-1601
MKC-1
mocetinostat
motexafin gadolinium
MVA-BN Her-2 vaccine
NAFB001
navitoclax
netupitant
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ON-01910
Oncohist
OncoVAX
Onyvax-105
OTS-102
ozarelix
p.DOM-WT1-37/p.DOM-WT1-126 DNA
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
PBI-1402
PCI-24781
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
retaspimycin
Reximmune-C
rindopepimut
rintatolimod
romurtide
S-488410
sagopilone
SCIB-1
seliciclib
sipuleucel-T
sotatercept
SPC-2996
ß-lapachone
SU-6668
Survivac
terameprocol
TG-4010
thymalfasin
tigapotide triflutate
tigatuzumab
tipapkinogene sovacivec
tipifarnib
TL-32711
TM-30339
triciribine phosphate
TroVax
TRU-016
vapreotide, immediate-release
velimogene aliplasmid
verpasep caltespen
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Apoptosis, Cancer Vaccines and Peptides.
    To find out more about Triple Analysis: Apoptosis, Cancer Vaccines and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Apoptosis, Cancer Vaccines and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lymphoma, Prostate Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Prostate Cancer and by the compound strategy of Antibodies. Learn More


Triple Analysis: Colorectal Cancer, Lymphoma and Pancreatic Cancer
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lymphoma and Pancreatic Cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Prostate Cancer, Cancer Vaccines and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Prostate Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Peptides). Learn More


Triple Analysis: Breast Cancer, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lymphoma and by the compound strategy of Antibodies. Learn More